Alpha-interferon improves survival and remission duration in P-190(BCR-ABL) positive adult acute lymphoblastic leukemia

Leukemia

Volumn 14, Issue 1, 2000, Pages 22-27

  Visani, G ^a,b   Martinelli, G ^a   Piccaluga, P ^a   Tosi, P ^a   Amabile, M ^a   Pastano, R ^a   Cavo, M ^a   Isidori, A ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

BGR ABL; Bone marrow transplantation; Interferon; Leukemia; Lymphoblastic; P 190

Indexed keywords

ALPHA INTERFERON; MERCAPTOPURINE; METHOTREXATE; RECOMBINANT ALPHA2A INTERFERON;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG TOLERABILITY; HUMAN; LEUKEMIA REMISSION; MAINTENANCE THERAPY; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION;

EID: 0033967641     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401641     Document Type: Article

References (54)

1. Mes-Masson A, Witte ON. Role of the abl oncogene in chronic myelogenous leukemia. Adv Cancer Res 1987; 49: 53-58.
2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
3. Butturini A, Arlinghaus RB, Gale RP. Concise report: BCR/ABL and leukemia. Leukemia Res 1996; 20: 525-529.
4. Takeda N, Masabumi S, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Med Sci 1999; 96: 203-207.
5. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K 562 leukemia cells unmasks associated tyrosine-kinase activity. Cell 1984; 37: 1035-1041.
6. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Nerian Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON. Expression of a distictive BCR-ABL oncogene in Ph′-positive acute lymphocytic leukemia (ALL). Science 1988; 239: 775-777.
7. Chan LL, Karhi KK, Rayter SJ, Heusterkamp N, Eridani S, Powles R, Lawler SD, Griffin J, Foulkes JG, Greaves MF, Wiedemann LM. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature 1987; 325: 635-644.
8. KurzrocK R, Shtalrid M, Romero P, Kloetzer WS, Talpaz M, Trujillo JM, Blick M, Beran M, Gutterman JU. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature 1987; 324: 631-635.
9. Lago TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
10. Nishimura J, Shibata K, Sadamura S, Takahira H, Hirata I, Umemura T, Nawata H, Okamura J. Differences in tyrosine phosphorylated proteins between cells expressing p210 and p190 bcr/abl. Int J Hematol 1992; 55: 227-233.
11. Kantarijan HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Truijllo J, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991: 78: 2411-2418.
12. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Jansenn JWG, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996; 10: 957-963.
13. Clarkson BD, Ellis S, Little C. Acute lymphoblastic leukemia in adults. Semin Oncol 1985; 12: 160-183.
14. Bloomfield CD, Wurster-Hill D, Peng G. Prognostic Significance of the Philadelphia Chromosome in Adult Acute Lymphoblastic Leukemia Alan R Liss: New York, 1990, pp 101-109.
15. Ghely GB, Bryant EM, Lee AM. Chimeric BCR-ABL messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive lymphoblastic leukemia. Blood 1991; 78: 4578-4584.
16. Martin H, Hoelzer D, Atta J. Autologous bone marrow transplantation in Ph′-positive/BCR-ABL positive acute lymphoblastic leukemia. Blood 1993; 82 (Suppl. 1): 167a.
17. Chao NJ, Forman SJ, Schmidt GM, Snyder DS, Amylon MD, Konrad PN, Nademanee AP, O'Donnell MR, Parker PM, Stein AS. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78: 1923-1927.
18. Brennan C, Weisdorf D, Kersey J. Bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph′ + ALL). Proc Am Soc Clin Oncol 1991 ; 10: 222.
19. Barrett AJ, Horowitz MM, Bortin MM for the International Bone Marrow Transplant Registry (IBMTR). HLA identical sibling bone marrow transplants for Ph′-chromosome positive acute lymphoblastic leukemia in first remission, Exp Hematol 1991; 18: 569-577.
20. Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldmann JM, Henslee-Downey PJ, Herzig RH, Speck B, Zwaan FE, Bortin MM. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79: 3067-3070.
21. Stockschlader M, Hegewisch-Becker S, Kruger W, Dieck A, Mross K, Hoffknecht M, Berger C, Kohlschutter B, Martin H, Peters S, Kabisch H, Kuse R, Weh H, Zander A. Bone marrow transplantation for Philadelphia positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 16: 663-667.
22. Forman SJ, O'Donnel MR, Nademanee AP, Snyder DS, Bierman PJ, Schmidt GM, Fahey JL, Stein AS, Parker PM, Blume KC. Bone marrow transplantation for patients with Philadelphia-positive acute lymphoblastic leukemia. Blood 1997; 70: 587-588.
23. Tura S, Baccarani M, Zuffa E. The Italian Cooperative Study Group on chronic myeloid leukemia IFN alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
24. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Cenacchi A, Carrara P, Clavio M, Gobbi M, Tura S. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Eur J Haematol 1996; 56: 608-312.
25. Guerrasio A, Martinelli G, Saglio G, Rosso C, Zaccaria A, Rosti G, Testoni N, Ambrosetti A, Izzi T, Sessarego M, Frassoni F, Gasparini P, Chiamenti A, Di Bartolomeo P, Pignatti PF. Minimal residual disease status in transplanted chronic myelogenous leukemia patients; low incidence of polymerase chain reaction positive cases among 48 long disease free subjects who received unmanipulated allogeneic bone marrow transplantation. Leukemia 1992; 6: 507-512.
26. Martinelli G, Gasparini P, Ambrosetti A, Battista R, Perona G. Pignatti PF. Molecular analysis of bcr breakpoint in Philadelphia chromosome rearrangements and correletion with prognosis and age of chronic myelogenous leukemia patients. In: CS Bartsocas, D Loukopoulos (eds). Genetics of Hematological Disorders. Hemisphere Publishing: Washington DC, 1990, pp 185-193.
27. Testoni N, Martinelli G, Farabegoli P. A new method of 'in cell RT-PCR' for the detection of bcr-abl transcript in chronic myeloid leukemia patients. Blood 1995; 87: 3822-:3827.
28. Frassoni F, Martinelli G, Saglio G, Sessarego M, Podestà M, Piaggio G, Farabegoli B, Zaccaria A, Testoni N, Remiddi B, Bacigalupo A, Di Bartolomeo P, Angrilli F, Falda M, Locatelli F, Izzi T, Gottardi E, Guerrasio A. Bcr/abl chimetic transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase. Bone Marrow Transplant 1995; 16: 595-601.
29. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, de Micheli D, Parziale A, Farnaci MN, Martinelli G, Salvatore G. Consistent amounts of acute leukemia-associated P190 BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996; 87, 1075-1080.
30. Martinelli G, Testoni N, Montefusco V, Amabile M, Saglio G, Ottaviani E, Terragna C, Bonifazzi F, De Vivo A, Pane F, Rosti G, Tura S. Detection of BCR-ABL transcript in chronic myelogenous leukemia patients by reverse-transcription polymerase chain reaction and capillary electrophoresis, Haematologica 1998, 83: 593-601.
31. Zinzani PL, Bendandi M, Visani G, Gherlinzoni G, Frezza G, Merla E, Manfroi S, Gozzetti A, Tura S. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 1996; 23: 577-582.
32. + cells to remove circulating tumor cells. Blood 1996; 87: 1625-1634.
33. Testoni N, Lemoli RM, Martinelli G, Carboni C, Pelliconi S, Ottaviani E, Ruggeri D, Rizzi S, Motta MR, Visani G, Tura S. Autologous PBSCT in acute myeloblastic leukemia and MDS. Evaluation of tumor cell contamination of leukaphereses by cytogenetic and molecular methods. Bone Marrow Transplant 1998; 22: 1065-1070.
34. Westbrook CA, Hooberman AL, Spino C. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762) Blood 1992; 80: 2983-2989.
35. Seeker-Walker LM, Craig JM, Hawkins JM. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukumia 1991; 5: 196-201.
36. Golz G, Weh H-J, Walter TA. Clinical and prognoslic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol 1992; 64; 97-101.
37. Mandelli F, Annino L, Ciolli S for the GIMEMA Group. Philadelphia chromosome (Ph 1) positive acute lymphoblastic leukemia (ALL) in adults: interim results of GIMEMA ALL 0288 pilot study. Blood 1993; 82 (Suppl. 1): 58a.
38. Preti A, O'Brien S, Giralt S. Philadelphia chromosome positive adult acute lympocytic leukemia - characteristics, treatment results, and prognosis. Blood 1993; 82 (Suppl 1): 329a.
39. Kantarjian HM, Walters RS, Keating MJ. Results of the vincristine, daunorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocitic leukemia. J Clin Oncol 1990; 8: 994-999.
40. Cassileth PA, Andersen JW, Hoagland HC. High-dose cytarabine therapy in adult acute lymphoblastic leukemia. In Gale RP, Hoelzer D (eds). Acute Lymphoblastic Leukemia. Alan R Liss: New York, 1990, pp 197-203.
41. Cuttner J, Mick R, Budman DR. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone. A CALGB study. Leukemia 1991; 5: 425-414.
42. Hass OA, Mor W, Gadner H, Bartram CR. Treatment of Ph-positive acute lymphoblastic leukemia with α-interferon (letter). Leukemia 1998; 2: 255.
43. Ohyashiki K, Ohyashiki JH, Tauchi T, Fujieda H, Hojo H, Ohtaka M, Saito M, Nakazawa S, Toyama K. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a pilot study which raises important questions. Leukemia 1991; 7, 611-614.
44. Schiffer CA, Larson RA, Bloomfield CD for the CALGB. Cancer and Leukemia Group B (CALGB) studies in acute lymphoeytic leukemia (ALL). Haematologica 1991; 76 (Suppl. 4): 106-111.
45. Hochaus A, Lin F, Reiter A. Quantification of residual disease in chronic myelogenous leukemia patients on IFN-α therapy by competitive plymerase chain reaction. Blood 1996; 87: 1549-1555.
46. Santucci MA, Visani G, Russo D. In vitro activity of alpha-interferon on granulocyte-macrophage precursors in chronic myeloid leukemia (CML): correlation with clinical responsiveness. Leuk Lymphoma 1992; 6: 155-160.
47. Santucci MA, Soligo D, Pileri S, Zuffa E, Testoni N, Tura S. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk Lymphoma 1993; 11 (Suppl.1): 113-118.
48. Dowding C, Guo AP, Osterholtz J, Siczkowski M, Goldman M, Gordon M. Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499-505.
49. Updhyaya G, Guba SC, Sih SA. Interferon-alpha restore the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88: 2131-2116.
50. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by connecting impaired β1 integrin receptor function. J Clin Invest 1994; 94: 384-391.
51. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells. Inhibition of hematopoietic growth factors and induction of interleukine-1 receptor antagonists. Blood 1994; 84: 4142-4150.
52. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 1991; 78: 2400-2406.
53. Muller CA, Waltz J, Zinser R, Buhring HJ, Steinke B, Schmidt H. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-α treatment. Ann Hematol 1991; 63: 259-261.
54. Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S. Auto-immune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myelogenous leukemia. Haematologica 1996; 81: 511-515.